Table 3. Anticoagulant activity of 6a, 6a-b, 6a-e, 6k, 6k-a and 6k-b.
| No. | FXa Ki (nM) | 2 × PT (μM) (Human) |
|---|---|---|
| 6a | 20.5 | 8.4 |
| 6a-b | 13.4 | 4.2 |
| 6a-e | 39.1 | 3.8 |
| 6k | 17.0 | 16.4 |
| 6k-a | 58.6 | 16.9 |
| 6k-b | 25.4 | 11.3 |
| rivaroxaban | 0.7 | 0.2 |
| No. | FXa Ki (nM) | 2 × PT (μM) (Human) |
|---|---|---|
| 6a | 20.5 | 8.4 |
| 6a-b | 13.4 | 4.2 |
| 6a-e | 39.1 | 3.8 |
| 6k | 17.0 | 16.4 |
| 6k-a | 58.6 | 16.9 |
| 6k-b | 25.4 | 11.3 |
| rivaroxaban | 0.7 | 0.2 |